Differential CSF biomarker levels in APOE-ε4-positive and -negative patients with memory impairment

被引:26
作者
Andersson, Christin
Blennow, Kaj
Johansson, Sven-Erik
Almkvist, Ove
Engfeldt, Peter
Lindau, Maria
Eriksdotter-Jonhagen, Maria
机构
[1] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Psychol, SE-14186 Stockholm, Sweden
[2] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Neurobiol Caring Sci & Soc, SE-14186 Stockholm, Sweden
[3] Univ Stockholm, Dept Psychol, S-10691 Stockholm, Sweden
[4] Univ Gothenburg, Clin Neurochem Lab, Dept Clin Neurosci, Gothenburg, Sweden
[5] Univ Orebro, Dept Clin Med, Family Med Res Ctr, Orebro, Sweden
[6] Univ Uppsala Hosp, Dept Publ Hlth & Caring Sci Geriatr, Uppsala, Sweden
关键词
episodic memory; cognitive decline; CSF biomarkers; apolipoprotein E genotype;
D O I
10.1159/000097354
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objectives: To investigate the relationships between episodic memory, APOE genotype, CSF markers (total tau, T-tau; phospho-tau, P-tau; beta-amyloid, A beta 42) and longitudinal cognitive decline. Methods: 124 memory clinic patients were retrospectively divided into 6 groups based on (i) episodic memory function (Rey Auditory Verbal Learning Test, RAVLT): severe, moderate or no impairment (SIM, MIM or NIM), and (ii) APOE genotype (epsilon 4+ or epsilon 4-). CSF marker levels and cognitive decline were compared across groups. Results: Episodic memory function, according to RAVLT scores, was significantly correlated with CSF marker levels only among epsilon 4+ subjects and not among epsilon 4- subjects. When comparing the 6 subgroups, SIM epsilon 4+ and MIM epsilon 4+ groups showed significantly lower A beta 42 levels than the other groups. T-tau and P- tau levels were significantly increased in SIM epsilon 4+ when compared to all the other groups, including the SIM epsilon 4- group. However, both SIM epsilon 4+ and SIM epsilon 4- declined cognitively during the follow-up. Conclusion: It remains to be determined whether APOE genotype affects the expression of biomarkers in CSF, or whether the different biomarker patterns reflect different types of disease processes in patients with progressive cognitive dysfunction. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:87 / 95
页数:9
相关论文
共 46 条
  • [1] Almkvist O, 1998, J NEURAL TRANSM-SUPP, P21
  • [2] Identifying patients at high and low risk of cognitive decline using Rey Auditory Verbal Learning Test among middle-aged memory clinic outpatients
    Andersson, C
    Lindau, M
    Almkvist, O
    Engfeldt, P
    Johansson, SE
    Jönhagen, ME
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2006, 21 (04) : 251 - 259
  • [3] INTELLECTUAL-FUNCTIONING IN A 70-YEAR-OLD URBAN-POPULATION
    ANDERSSON, E
    BERG, S
    LAWENIUS, M
    SVANBORG, A
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1978, 57 (01) : 59 - 66
  • [4] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
    Andreasen, N
    Hesse, C
    Davidsson, P
    Minthon, L
    Wallin, A
    Winblad, B
    Vanderstichele, H
    Vanmechelen, E
    Blennow, K
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (06) : 673 - 680
  • [5] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
    Andreasen, N
    Minthon, L
    Davidsson, P
    Vanmechelen, E
    Vanderstichele, H
    Winblad, B
    Blennow, K
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 373 - 379
  • [6] Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease
    Arnáiz, E
    Almkvist, O
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 : 34 - 41
  • [7] Bartfai A., 1994, WECHSLER ADULT INTEL
  • [8] CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry
    Blennow, K
    Vanmechelen, E
    [J]. BRAIN RESEARCH BULLETIN, 2003, 61 (03) : 235 - 242
  • [9] tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease?
    Blennow, K
    Wallin, A
    Agren, H
    Spenger, C
    Siegfried, J
    Vanmechelen, E
    [J]. MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) : 231 - 245
  • [10] CSF biomarkers for mild cognitive impairment
    Blennow, K
    [J]. JOURNAL OF INTERNAL MEDICINE, 2004, 256 (03) : 224 - 234